Aldeyra Therapeutics SEC filings document a biotechnology issuer focused on investigational therapies for immune-mediated diseases and formal disclosures tied to its RASP modulator pipeline. Recent 8-K reports furnish press releases and corporate presentations covering reproxalap regulatory review, clinical and preclinical program updates, pipeline prioritization, and FDA-related disclosures for dry eye disease.
The filing record also covers governance and capital-structure matters, including definitive proxy materials for annual meeting proposals and director elections, board-transition disclosures, and the payoff and termination of the Hercules Credit Facility. These filings group Aldeyra's public-company record around operating updates, risk and forward-looking-statement disclosures, stockholder voting matters, and financing arrangements.
Aldeyra Therapeutics is holding its 2026 annual stockholder meeting on June 9, 2026 at 9:00 a.m. in Boston. Investors will vote on electing CEO Todd C. Brady as the sole Class III director, ratifying BDO USA, P.C. as auditor for 2026, and approving an advisory say-on-pay resolution.
BDO has audited Aldeyra since 2013 and received audit fees of $522,184 in 2025. For 2025, Brady’s compensation totaled $4.7 million, including $700,000 salary, a $189,000 bonus, and option awards valued at $3.8 million. For 2026, his salary is set at $750,000 with a $450,000 target bonus and significant new equity and cash-based awards.
The board is staggered into three classes and is majority independent, with separate chair and CEO roles and established audit, compensation, and nominating/governance committees. Directors receive cash retainers and stock options under a defined non-employee director compensation plan, and Aldeyra has adopted a clawback policy and insider trading restrictions.
Aldeyra Therapeutics, Inc. reported that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders. He will continue to serve as a director until his term expires at that meeting.
The company stated that Mr. Joyce’s decision was not the result of any disagreement with Aldeyra, indicating an orderly and voluntary board transition rather than a dispute-driven departure.
Aldeyra Therapeutics, Inc. has fully repaid its debt under the Hercules Credit Facility. On April 1, 2026, the company paid off outstanding borrowings of $15 million, and all remaining commitments under the loan agreement were terminated in line with its April 1, 2026 maturity.
The Hercules Credit Facility, originally entered in March 2019, is now fully closed. The company notes that its cash, cash equivalents, and marketable securities as of December 31, 2025 are expected to support operations into 2028, indicating sufficient liquidity after the loan repayment.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady received new equity-based compensation awards. He was granted a stock option covering 1,880,510 shares of common stock at an exercise price of $1.77 per share. This option vests in equal monthly installments over 48 months of continuous service after January 1, 2026 and expires on March 26, 2036.
Brady was also awarded 632,318 bonus units, which vest in equal annual installments over four years beginning on March 27, 2026, contingent on continued service. Each vested bonus unit entitles him to a cash payment equal to the closing price per share of Aldeyra’s common stock on the payment date, made on the earlier of four years from grant or a Change of Control. These are compensation grants, not open-market share purchases or sales.
Aldeyra Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned, representing 0% of the Common Stock as disclosed in the amendment.
The filing states Vanguard completed an internal realignment on January 12, 2026 and, "in accordance with SEC Release No. 34-39538 (January 12, 1998)", certain subsidiaries will report ownership separately.
Aldeyra Therapeutics director Richard Douglas bought more company stock in the open market. He acquired 70,000 shares of common stock in an open-market purchase at $1.40 per share. Following this transaction, he directly owns 195,000 shares, indicating a larger personal stake in Aldeyra Therapeutics.
Aldeyra Therapeutics, Inc. Principal Financial Officer Michael Alfieri reported an open-market purchase of common stock. On this transaction date, he bought 5,000 shares at a price of $1.42 per share. Following the purchase, his direct ownership increased to 7,500 common shares.
Aldeyra Therapeutics received a Complete Response Letter from the U.S. FDA for its reproxalap New Drug Application to treat the signs and symptoms of dry eye disease. The FDA wrote that the application lacks substantial evidence of efficacy, citing inconsistent study results and questioning the reliability of positive findings.
No safety or manufacturing concerns were identified, but the FDA concluded that the totality of clinical evidence does not support effectiveness. Aldeyra plans to request a Type A meeting to understand what is required for potential approval and acknowledges that additional studies or trials could be required, which would increase costs and delay commercialization. As of December 31, 2025, the company held $70 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028.
Aldeyra Therapeutics outlines its strategy as a late‑stage biotechnology company developing RASP modulators and the intravitreal methotrexate product ADX‑2191 for immune‑mediated eye and systemic diseases. Lead candidate reproxalap targets dry eye disease and allergic conjunctivitis, but has received multiple FDA Complete Response Letters requiring additional symptom‑focused trials.
The company has granted AbbVie an exclusive option to co‑develop and commercialize reproxalap, which, if exercised, would include a $100.0 million upfront payment (offset by prior option fees) and up to about $300.0 million in milestones, plus a 60/40 U.S. profit‑share and ex‑U.S. royalties. ADX‑2191 holds orphan and fast track designations in certain indications, with an FDA‑agreed SPA for primary vitreoretinal lymphoma and expansion plans in retinitis pigmentosa.
Perceptive Advisors and affiliates report a 7.0% stake in Aldeyra Therapeutics, Inc. They beneficially own 4,185,632 shares of common stock, based on 60,162,773 shares outstanding as of November 4, 2025. The Perceptive Life Sciences Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member.
The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Aldeyra, consistent with a passive investment under Schedule 13G.